Theratechnologies (THTX) Appoints Frank Holler to its Board

Theratechnologies Inc. (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the appointment of Mr. Frank Holler as a new independent member to its Board of Directors.

“The appointment of Frank Holler adds important expertise and capabilities to the Board. Frank brings extensive knowledge and experience in the North American capital markets and has a well-recognized track record in the biotech industry having been involved in the establishment and growth of four of Canada’s most successful biopharmaceutical companies,” said Ms. Dawn Svoronos, Chair of the Board, Theratechnologies Inc.

“On behalf of the Board of Directors at Theratechnologies, it is my pleasure to welcome Frank. He arrives at a crucial time in Theratechnologies’ history as the Company continues to grow its commercial business globally and advance its exciting pipeline, namely moving forward its lead Peptide-Drug Conjugate, TH1902, through a Phase 1 clinical trial for the potential treatment of solid tumors expressing the sortilin receptor and advancing the development program for tesamorelin in Nonalcoholic Steatohepatitis (NASH) in the general population. Frank’s in-depth experience at growing shareholder value and strong knowledge of the challenges and opportunities in the biotech industry will be great assets for the Board,” added Ms. Svoronos.

You May Also Be Interested In

• Grok Bot launches in early beta for select subscribers
• Keurig Dr Pepper names Cardinal Health CFO to its board
• Bank of America to acquire up to 49.9% stake in Jio Credit Limited